Published in Healthcare Finance, Tax and Law Weekly, July 25th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Critical Therapeutics, Inc.
Report 1: Critical Therapeutics, Inc. (Nasdaq: CRTX) announced that the U.S. Food and Drug Administration (FDA) has approved Dey, L.P.'s (DEY) New Drug Application for Perforomist(TM) (formoterol fumarate) Inhalation Solution for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD). Perforomist(TM) Inhalation Solution was approved as a 505(b)2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.